TABLE OF CONTENTS

ABSTRACT I

PROLOGUE III

ACKNOWLEGEMENT V

LIST OF ABBERVATIONS VIII

LIST OF TABLES XI

LIST OF FIGURES XIII

Chapter 1

1 INTRODUCTION AND BIOLOGICAL RELEVANCE

1.1 INTRODUCTION 1

1.1.1 Lysosomal storage disorders: A brief overview 1

1.1.2 Tay-Sachs disease: An introduction 3

1.2 BIOLOGICAL RELEVANCE 4

1.2.1 Overview 4

1.2.1.1 History of Tay-Sachs disease (TSD) 4

1.2.1.2 Gangliosides structures and locations 6

1.2.1.3 Biosynthesis and Catabolism of Gangliosides 8

1.2.1.4 Function of Ganglioside 10

1.2.1.5 Gangliosides and diseases 10

1.2.2 Biochemical consequence in Tay-Sachs disease (TSD) 10

1.2.2.1 Identification of the metabolic defect in TSD by the biochemical Link between β-Hexosaminidase enzyme activity and GM2 gangliosidoses 10

1.2.2.2 Subunit structure of Hexosaminidase 12

1.2.2.3 Isolation of cDNA clones for the subunits of Hex-A 14

1.2.2.4 Substrate specificity of the Hex isozymes 14

1.2.2.5 3D structure Hex-A/B 14

1.2.2.6 Biosynthesis and Lysosomal targeting of Hexosaminidase 16

1.2.3 GM2 gangliosidosis 17

1.2.3.1 Tay-Sachs disease (TSD) 17

1.2.3.2 Sandhoff disease (SD) 18
1.2.3.3 GM2 activator protein deficiency (GM2AP) 19
1.2.4 Types and clinical description of Tay-Sachs disease 19
1.2.4.1 Infantile Tay-Sachs disease (ITSD) 19
1.2.4.2 Juvenile Tay-Sachs disease 20
1.2.4.3 Late-Onset or Adult Tay-Sachs disease (LOTD) 21
1.2.4.4 B1 Variants of Tay-Sachs disease 21
1.2.5 The critical threshold hypothesis 22
1.2.6 Predominance of Tay-Sachs disease 23
1.2.6.1 International scenario 23
1.2.6.2 National scenario 23
1.2.7 Molecular Characterization of the *HEXA* Gene 23
1.2.8 Mutations in the HEXA gene associated with the Tay-Sachs disease 24
1.2.9 Genotype-Phenotype correlations 40
1.2.10 Lacunae of Tay-Sachs disease 41

Chapter 2

2 RATIONAL AND OBJECTIVE
2.1 RATIONAL 42
2.2 BIOLOGICAL RELEVANCE 42

Chapter 3

3 MATERIALS AND METHODS
3.1 STUDY SUBJECTS 44
3.1.1 Patients and Controls 44
3.1.2 Sample size 44
3.1.3 Ethics Statement 45
3.2 WORK PLAN 45
3.3 MATERIALS 45
3.3.1 Sample types 45
3.3.2 Buffer and Reagents 46
3.3.3 Laboratory equipments used 49
3.3.4 Online bioinformatical and statistical tools used 49
3.4 METHODS 50

3.4.1 Lysosomal Enzyme activity assay 50
3.4.1.1 Isolation of peripheral blood leucocytes for postnatal diagnosis 50
3.4.1.2 Collections and cultured CV/AF for prenatal diagnosis 51
3.4.1.3 Extraction of cells 51
3.4.1.4 Protein concentration in leucocytes using Lowry method 52
3.4.1.5 Measurement of Hexosaminidase-A (Hex-A) and Total-Hexoasminidase (total-Hex) activity using LS55 spectrophotometer 52
3.4.1.6 Quality control 54
3.4.1.7 Statistic analysis 54
3.4.2 Molecular analysis 54
3.4.2.1 Genomic DNA Extraction 54
3.4.2.2 Determination of purity and concentration of isolated DNA 54
3.4.2.3 Integrity of DNA 55
3.4.2.4 Common mutations screening 56
3.4.2.5 DNA sequencing *HEXA* gene (Hexosaminidase-A) 58
3.4.2.6 Multiplex Ligation dependent Probe Amplification (MLPA) 60
3.4.2.7 DNA sequencing *GM2A* gene 61
3.4.3 Bioinformatics analysis 63
3.4.3.1 Prediction tools (Bioinformatics softwares) predicting non-synonymous and splice site sequence variations 63
3.4.3.2 Multiple sequence alignment of HEXA gene 63
3.4.2.3 Protein modeling and molecular docking studies 63
3.4.4 Haplotype analysis 64
3.4.5 Established simple cost effective PCR based methods for common mutations..... 64
3.4.5.1 Established ARMS-PCR for E462V mutation 64
3.4.5.2 Established PCR-RFLP for D322Y mutation 65

Chapter 4

4 RESULTS
4.1 BIOCHEMICAL ANALYSIS 67
4.1.1 Standard curve for Hexosaminidase-A (Hex-A) and total-Hexosaminidase (total-Hex) activity 67
4.1.2 Measurement of Hexosaminidase-A (Hex-A) and total-Hexosaminidase (total-Hex) activity in Leucocytes 68

4.1.3 Measurement of Hexosaminidase-A% (%Hex-A) and total-Hexosaminidase (total-Hex) activity in leucocytes for carrier detection 70
4.1.4 Measurement of Hexosaminidase-A (Hex-A) and total-Hexosaminidase (total-Hex) activity in CT/AF cells for prenatal diagnosis 71
4.1.5 Quality Control 71
4.1.6 Account for Tay-Sachs disease (TSD) 75
4.1.7 Analysis of TSD patients 76
4.1.7.1 Provincial distribution of TSD patients 76
4.1.7.2 Demographical profile of TSD patients 76
4.1.7.3 Age of onset and Age at diagnosis 76
4.1.7.4 Clinical Profile of TSD patients 78
4.2 MOLECULAR ANALYSIS 79
4.2.1 Common variants study 81
4.2.2 Bi-directional sequencing of the *HEXA* gene to identify known/ novel mutations 81
4.2.2.1 Study of *HEXA* gene in enzymatically affected infantile/juvenile TSD 81
4.2.2.2 Study of *HEXA* gene in carrier parents 91
4.2.3 Multiple ligation probe analysis (MLPA) study of *HEXA* gene 94
4.2.4 Bidirectional sequencing of *GM2A* gene in enzymatically normal patients to rule out AB variant form of TSD (GM2 activator protein deficiency) 97
4.2.5 To evolve a cost effective DNA strategy to prevalent mutations in our population through identification of the carrier frequency by mass screening 97
4.3 BIOINFORMATICS ANALYSIS 98
4.3.1 Prediction of novel and known variants of *HEXA* gene 98
4.3.2 Multiple sequence alignment 102
4.3.3 Protein modeling and molecular docking study 103
4.3.4 Haplotype analysis 108
4.4 GENOTYPE-PHENOTYPE CORRELATION OF TSD PATIENTS 110
4.5 PRENATAL DIAGNOSIS AND GENETIC COUNSELING 121

Chapter 5

5 DISSCUSION 124

Chapter 6

6 CONCLUSION, SUMMARY AND FUTURE PROSPECT

6.1 CONCLUSION 144

6.2 SUMMARY AND FUTURE PROSPECT 145

REFERENCES 147

PEER REVIEW PUBLICATIONS & POSTER/ORAL PRESENTATIONS 168

ANNEXURE I 174

ANNEXURE II 184

ANNEXURE III 185

SUPPLEMENTARY MATERIALS